Dissecting Histone Deacetylase 3 in Multiple Disease Conditions: Selective Inhibition as a Promising Therapeutic Strategy | Journal of Medicinal Chemistry
Dissecting Histone Deacetylase 3 in Multiple Disease Conditions: Selective Inhibition as a Promising Therapeutic Strategy | Journal of Medicinal Chemistry
Frontiers | Recent Update of HDAC Inhibitors in Lymphoma
A Randomized Comparison of Modified Intermediate-dose Ara-C versus High-dose Ara-C in Post-remission Therapy for Acute Myeloid Leukemia | Anticancer Research
Cytarabine (Cytosine β-D-arabinofuranoside) | DNA Synthesis Inhibitor | MedChemExpress
Conserved in vitro expression of HDAC repressors and modulators of ARAC... | Download Scientific Diagram
AML consolidation therapy: timing matters | Journal of Cancer Research and Clinical Oncology
HDAC4 Governs a Transcriptional Program Essential for Synaptic Plasticity and Memory: Cell
A Randomized Investigation of High-Dose Versus Standard-Dose Cytosine Arabinoside With Daunorubicin in Patients With Previously Untreated Acute Myeloid Leukemia: A Southwest Oncology Group Study - ScienceDirect
Epigenetic therapies in acute myeloid leukemia: the role of hypomethylating agents, histone deacetylase inhibitors and the combination of hypomethylating agents with histone deacetylase inhibitors | Chinese Medical Journal
Molecules | Free Full-Text | Natural Compound Histone Deacetylase Inhibitors (HDACi): Synergy with Inflammatory Signaling Pathway Modulators and Clinical Applications in Cancer
HDAC deacethylation mechanism in leukemic cells . Overexpression of... | Download Scientific Diagram
Expression profiles of classes I, II, and IV HDACs and sensitivities to... | Download Scientific Diagram
Ribonucleotide reductase inhibitors suppress SAMHD1 ara‐CTPase activity enhancing cytarabine efficacy | EMBO Molecular Medicine
![PDF] Panobinostat Enhances Cytarabine and Daunorubicin Sensitivities in AML Cells through Suppressing the Expression of BRCA1, CHK1, and Rad51 | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/f668094fba2a13c35b48a8e49e9586d85158d88a/11-Figure6-1.png "PDF] Panobinostat Enhances Cytarabine and Daunorubicin Sensitivities in AML Cells through Suppressing the Expression of BRCA1, CHK1, and Rad51 | Semantic Scholar")
PDF] Panobinostat Enhances Cytarabine and Daunorubicin Sensitivities in AML Cells through Suppressing the Expression of BRCA1, CHK1, and Rad51 | Semantic Scholar
Targeting HDAC3, a new partner protein of AKT in the reversal of chemoresistance in acute myeloid leukemia via DNA damage response | Leukemia
Romidepsin enhances the efficacy of cytarabine in vivo, revealing histone deacetylase inhibition as a promising therapeutic strategy for KMT2A-rearranged infant acute lymphoblastic leukemia | Haematologica
Frontiers | Increased HDAC Activity and c-MYC Expression Mediate Acquired Resistance to WEE1 Inhibition in Acute Leukemia
PRINCIPLES OF ANTINEOPLASTIC THERAPY
HDAC inhibitors promote granulocytic differentiation. (A)... | Download Scientific Diagram
IN ACUTE MYELOID LEUKEMIA, THE USE IN INDUCTION OF STANDARD DOSE ARA-C IS ASSOCIATED WITH A BETTER QUALITY OF RESPONSE AS COMPARED TO AN INDUCTION REGIMEN. - ppt download
Co-targeting of HDAC, PI3K, and Bcl-2 results in metabolic and transcriptional reprogramming and decreased mitochondrial function in acute myeloid leukemia - ScienceDirect
IN ACUTE MYELOID LEUKEMIA, THE USE IN INDUCTION OF STANDARD DOSE ARA-C IS ASSOCIATED WITH A BETTER QUALITY OF RESPONSE AS COMPARED TO AN INDUCTION REGIMEN. - ppt download
Cancers | Free Full-Text | HDAC Inhibitors in Acute Myeloid Leukemia
Biomedicines | Free Full-Text | Understanding Failure and Improving Treatment Using HDAC Inhibitors for Prostate Cancer
